ATRYS HEALTH, S.A. | Sales 2024 * | 223M 238M | Sales 2025 * | 240M 256M | Capitalization | 219M 234M |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 | Net income 2025 * | 8M 8.55M | EV / Sales 2024 * | 1.68 x |
| Net Debt 2024 * | 155M 166M | Net Debt 2025 * | 121M 129M | EV / Sales 2025 * | 1.42 x |
| P/E ratio 2024 * |
-66.8
x | P/E ratio 2025 * |
25
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.57% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 07-06-12 | |
| Director of Finance/CFO | - | 15-07-31 | |
| Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 48 | 16-01-31 | |
| Director/Board Member | 69 | - | |
| Director/Board Member | - | - |
Atrys Health SA, formerly Europath Biosciences SL, is Spain-based company primarily engaged in the predictive and personalized oncology therapies. It operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. It has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The Company has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.
| 1st Jan change | Capi. | |
|---|---|---|
| -14.92% | 84.87B | |
| +13.30% | 83.08B | |
| +10.92% | 29.4B | |
| -12.71% | 16.72B | |
| -3.06% | 16.4B | |
| -2.63% | 15.04B | |
| -3.97% | 11.88B | |
| -1.42% | 11.88B | |
| -31.75% | 11.86B |
